SUNRISE, Fla., July 29, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that they have agreed to terms to enter into a license agreement with Airspeed Equity regarding four separate Bioheart patents. The proposed license agreement will have great benefits to both companies: Airspeed will be granted exclusive rights to these patents and all products associated with the patents. Airspeed will pay Bioheart milestone payments and royalties based on sales of potential products. Mike Tomas, President and CEO, stated, “Bioheart is currently focused on our core technology of muscle stem cells for congestive heart failure patients and we are excited about the opportunity to work with Airspeed to bring other Bioheart technologies to market.”
